Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Protagenic Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, NY AND SANTA BARBARA, CA, JULY 30, 2025  PRISM MEDIAWIRE  PROTAGENIC THERAPEUTICS, INC. (NASDAQ: PTIX) (THE COMPANY) TODAY ANNOUNCES THAT ON JULY 18, 2025, THE JAPANESE PATENT OFFICE GRANTED PATENT JP 7714571B, A PATENT WHICH RUNS UNTIL MARCH 31, 2041.

PROTAGENIC THERAPEUTICS ANNOUNCES GRANT OF NEW PATENT IN JAPAN FOR ITS MODIFIED STILBENOID PROGRAM DRUG CANDIDATES

NEW YORK AND SANTA BARBARA, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- PROTAGENIC THERAPEUTICS, INC. (NASDAQ: PTIX) (THE COMPANY) TODAY ANNOUNCES THAT ON JULY 18, 2025, THE JAPANESE PATENT OFFICE GRANTED PATENT JP 7714571B, A PATENT WHICH RUNS UNTIL MARCH 31, 2041.

NEW YORK, NY / ACCESS NEWSWIRE / MAY 21, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") ANNOUNCED TODAY THAT WARRANT EXCHANGES AND EXERCISES OVER THE LAST FOUR TRADING DAYS HAVE GENERATED $3.1 MILLION IN CASH. THE PROCEEDS WILL FUND WORKING-CAPITAL NEEDS AND ADVANCE THE COMPANY'S PEPTIDE-BASED DRUG CANDIDATES FOR STRESS-RELATED AND CENTRAL-NERVOUS-SYSTEM DISORDERS.

PROTAGENIC THERAPEUTICS RECEIVES $3.1 MILLION FROM RECENT WARRANT ACTIVITY

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS NEWSWIRE / MAY 19, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") AND PHYTANIX BIO INC. HAVE ENTERED INTO A DEFINITIVE SHARE EXCHANGE AGREEMENT PURSUANT TO WHICH THE TWO ENTITIES WILL COMBINE IN AN ALL-STOCK TRANSACTION (THE "COMBINATION"). THE COMBINED ENTITY, TO BE CALLED PHYTANIX, INC., WILL BRING TOGETHER TWO PIPELINES FOCUSED ON STRESS-RELATED AND CNS DISORDERS, FIVE PRECLINICAL ASSETS AND ONE CLINICAL-STAGE ASSET.

PROTAGENIC THERAPEUTICS AND PHYTANIX ANNOUNCE BUSINESS COMBINATION TO FORM NEUROACTIVE BIOPHARMACEUTICAL COMPANY WITH SIX DRUG CANDIDATES IN DEVELOPMENT INCLUDING TREATMENTS FOR OBESITY AND METABOLIC DISORDERS

MEASURE TAKEN TO COMPLY WITH NASDAQ RULE 5550(A)(2) REGARDING MINIMUM BID PRICE NEW YORK, NY / ACCESS NEWSWIRE / APRIL 29, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) ("PROTAGENIC THERAPEUTICS" OR THE "COMPANY"), A LEADER IN BIOPHARMACEUTICAL INNOVATION, TODAY ANNOUNCED THAT THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED A 1-FOR-14 REVERSE STOCK SPLIT OF THE COMPANY'S ISSUED AND OUTSTANDING COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE "COMMON STOCK") TO BE EFFECTIVE 12:01 A.M., EASTERN TIME, ON MAY 5, 2025.

PROTAGENIC THERAPEUTICS TO EFFECT 1-FOR-14 REVERSE STOCK SPLIT

NEW YORK, NY / ACCESSWIRE / NOVEMBER 5, 2024 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) ("PROTAGENIC THERAPEUTICS" OR THE "COMPANY"), A LEADER IN BIOPHARMACEUTICAL INNOVATION, ANNOUNCED TODAY THAT ON NOVEMBER 4, 2024 IT CLOSED ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT PURSUANT TO A PURCHASE AGREEMENT (THE "PURCHASE AGREEMENT") FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK, SERIES A COMMON STOCK PURCHASE WARRANTS TO PURCHASE AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK, WITH AN EXERCISE PRICE OF $0.64 PER SHARE, WHICH ARE EXERCISABLE ON THE TRADING DAY IMMEDIATELY FOLLOWING THE STOCKHOLDER APPROVAL DATE (AS DEFINED IN THE PURCHASE AGREEMENT) FOR A TERM OF EIGHTEEN (18) MONTHS FROM THE STOCKHOLDER APPROVAL DATE, AND SERIES B COMMON STOCK PURCHASE WARRANTS TO PURCHASE AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $0.64 PER SHARE, WHICH ARE EXERCISABLE ON THE TRADING DAY IMMEDIATELY FOLLOWING THE STOCKHOLDER APPROVAL DATE FOR A TERM OF FIVE (5) YEARS FROM THE STOCKHOLDER APPROVAL DATE. THE PURCHASE PRICE OF EACH SHARE OF COMMON STOCK AND ASSOCIATED COMMON STOCK PURCHASE WARRANTS WAS $0.64 ($0.89 IN THE CASE OF INSIDERS).

PROTAGENIC THERAPEUTICS ANNOUNCES CLOSING OF PRIVATE PLACEMENT FOR AGGREGATE GROSS PROCEEDS OF $1.275 MILLION

NEW YORK, NY / ACCESSWIRE / OCTOBER 29, 2024 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) ("PROTAGENIC THERAPEUTICS" OR THE "COMPANY"), A LEADER IN BIOPHARMACEUTICAL INNOVATION, ANNOUNCED TODAY IT HAS ENTERED INTO A PURCHASE AGREEMENT (THE "PURCHASE AGREEMENT") FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU OF SHARES OF COMMON STOCK), SERIES A COMMON STOCK PURCHASE WARRANTS TO PURCHASE AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK, WITH AN EXERCISE PRICE OF $0.64 PER SHARE, WHICH ARE EXERCISABLE ON THE TRADING DAY IMMEDIATELY FOLLOWING THE STOCKHOLDER APPROVAL DATE (AS DEFINED IN THE PURCHASE AGREEMENT) FOR A TERM OF EIGHTEEN (18) MONTHS FROM THE STOCKHOLDER APPROVAL DATE (AS DEFINED IN THE PURCHASE AGREEMENT), AND SERIES B COMMON STOCK PURCHASE WARRANTS TO PURCHASE AN AGGREGATE OF 1,948,295 SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $0.64 PER SHARE, WHICH ARE EXERCISABLE ON THE TRADING DAY IMMEDIATELY FOLLOWING THE STOCKHOLDER APPROVAL DATE FOR A TERM OF FIVE (5) YEARS FROM THE STOCKHOLDER APPROVAL DATE. THE PURCHASE PRICE OF EACH SHARE OF COMMON STOCK AND ASSOCIATED COMMON STOCK PURCHASE WARRANTS WILL BE $0.64 ($0.89 IN THE CASE OF INSIDERS).

PROTAGENIC THERAPEUTICS ANNOUNCES PRICING OF PRIVATE PLACEMENT FOR AGGREGATE GROSS PROCEEDS OF $1.275 MILLION

NEW YORK, NY / ACCESSWIRE / MAY 1, 2024 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A LEADER IN BIOPHARMACEUTICAL INNOVATION, TODAY ANNOUNCED THE COMPLETION OF ENROLLMENT IN THE SINGLE DOSE PORTION OF ITS PHASE 1 TRIAL INVOLVING PT00114, ITS SYNTHETIC STRESS-REGULATING PEPTIDE, FOR TREATING NEUROPSYCHIATRIC DISORDERS. THIS MARKS A SIGNIFICANT MILESTONE WITH THE ENROLLMENT OF 30 SUBJECTS ACROSS FIVE COHORTS, RECEIVING DOSES UP TO 1,000 MICROGRAMS.

PROTAGENIC THERAPEUTICS COMPLETES ENROLLMENT IN SINGLE DOSE PORTION OF PHASE 1 OF INNOVATIVE STRESS DISORDER TRIAL

CHIEF OPERATING OFFICER TO PRESENT KEY ADVANCES AT PEPTIDE THERAPEUTICS SUMMIT NEW YORK, NY / ACCESSWIRE / APRIL 17, 2024 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A PIONEER IN BIOPHARMACEUTICAL RESEARCH, ANNOUNCED TODAY THAT DR. ANDREW SLEE, CHIEF OPERATING OFFICER, WILL PRESENT A TALK ON PT00114, THE COMPANY'S PROMISING NEW DRUG CANDIDATE, AT THE PEPTIDE BASED THERAPEUTIC SUMMIT IN BOSTON. TITLED "NOVEL BLOOD-BRAIN BARRIER PENETRATING PEPTIDE: OPENING NEW DOORS IN NEURO-PSYCHIATRIC TREATMENT," DR. SLEE'S TALK WILL FOCUS ON THE GROUNDBREAKING STRUCTURE OF PT00114, DESIGNED TO EFFICIENTLY CROSS THE BLOOD-BRAIN BARRIER AND UNLOCK NEW POTENTIAL IN TREATING SERIOUS NEURO-PSYCHIATRIC CONDITIONS.

PROTAGENIC THERAPEUTICS' INNOVATIVE PEPTIDE PT00114 TO BE HIGHLIGHTED AT BOSTON SUMMIT

TRANSITIONED FROM PRE-CLINICAL TO CLINICAL STAGE COMPANY IN FY 2023 PHASE 1/2A TRIAL, DESIGNED TO ASSESS BOTH HEALTHY VOLUNTEERS AND PATIENTS DIAGNOSED WITH TREATMENT-RESISTANT DEPRESSION, PTSD OR GENERALIZED ANXIETY DISORDER, PROGRESSING THROUGH PHASE 1 PORTION PLANS TO ENROLL FINAL TWO OUT OF FIVE COHORTS INTO THE SINGLE DOSE PORTION OF THE PHASE 1 TRIAL WITHIN THE NEXT MONTH NEW YORK, NY / ACCESSWIRE / APRIL 1, 2024 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A LEADER IN BIOPHARMACEUTICAL INNOVATION, TODAY PROVIDED A CORPORATE UPDATE AND REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2023. "IN 2023, PROTAGENIC THERAPEUTICS ACHIEVED A SIGNIFICANT MILESTONE AS WE BEGAN ENROLLING PATIENTS FOR OUR NEUROPEPTIDE DRUG CANDIDATE, PT00114," SAID DR. GARO ARMEN, EXECUTIVE CHAIRMAN.

Protagenic Therapeutics, Inc.

PTIX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Protagenic Therapeutics, Inc.

PTIX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PTIX